Exicure Signs Parkinson's Device Deal; Plans 20%-100% NeuroQ Stake Via Share Issuance
XCUR sits 18% above its 52-week low of $0.777 on light trading volume (0.1× avg).
Summary
Exicure signed a November 19 agreement with NeuroQ Biologics and Laonz to move into Parkinson's disease smart-glasses technology, intending to buy 20% to 100% of NeuroQ largely with Exicure shares and fund up to $500,000 of development. Final terms, share ratio and approvals are still open.
Key Events · M&A and Partnerships · XCUR
-
Parkinson's Device Expansion Agreement
On November 19, 2026 Exicure entered a Strategic Business Expansion and Investment Agreement with NeuroQ Biologics Inc. and Laonz Co., Ltd. covering X-CUE augmented-reality smart glasses for Parkinson's freezing of gait.
-
Stock-Funded 20%-100% NeuroQ Stake
Exicure intends to acquire an equity interest ranging from 20% to 100% in NeuroQ, primarily by issuing Exicure common shares in exchange for NeuroQ shares held by Laonz; the final percentage and share exchange ratio are undetermined.
-
Up to $500,000 Development Funding
Following the share acquisition, Exicure intends to provide up to US$500,000 for X-CUE clinical evaluation, regulatory work, manufacturing preparation and commercialization, subject to approvals and funding availability.
-
Terms and Approvals Still Open
Final acquisition percentage, exchange ratio and other terms require subsequent written agreements plus corporate, regulatory and Nasdaq approvals; X-CUE's planned clinical evaluation is expected to run about six months.
Analysis · XCUR · Life Sciences
Exicure is pivoting part of its business into Parkinson's disease medical devices through a new agreement with NeuroQ Biologics and Laonz. The company intends to acquire 20% to 100% of NeuroQ, paid mostly in Exicure stock rather than cash, and to put up to $500,000 into developing the X-CUE smart-glasses technology. That structure matters for a company this small: the share-based purchase means dilution whose size is still unknown, and the $500,000 funding commitment is a real cash call against a balance sheet that already carried a going concern warning. No acquisition percentage, exchange ratio, or definitive terms are set yet, so the deal is an intent, not a completed transaction. It also lands days before the December 2, 2026 shareholder vote on a $10 million private placement authorization and ahead of the December 2, 2026 Nasdaq equity-compliance deadline.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XCUR was trading at $0.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6M. The 52-week trading range was $0.78 to $9.48. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.